Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net loss	$ (261,658)	$ (194,119)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	2,303	1,667
Net (accretion) amortization on investment securities	(1,519)	217
Non-cash interest expense	12,642	8,244
Stock-based compensation expense	35,587	32,405
Remeasurement (gain) loss on embedded derivatives liabilities	(3,668)	657
Provision for excess and obsolete inventories	2,246
Loss on assets disposal	14	50
Changes in operating assets and liabilities:
Inventories	(15,597)
Trade and other receivables, net	(694)
Unbilled - collaboration and license revenue	(3,178)
Prepaid research and development	(229)	5,411
Prepaid manufacturing	(1,738)
Prepaid expenses and other current assets	(1,286)	(6,087)
Prepaid and other long-term assets	(2,852)	(4,395)
Accounts payable	4,749	3,426
Accrued compensation and employee benefits	(3,329)	4,104
Accrued research and development	(28,298)	326
Accrued and other liabilities	5,044	2,081
Deferred revenue	(180)	(12,743)
Notes payable, long term debt and long term obligation to collaborator	(316)
Other long-term liabilities	(720)	(657)
Net cash used in operating activities	(262,677)	(159,413)
Investing activities
Purchases of property and equipment	(1,577)	(1,542)
Purchases of intangible assets		(5,000)
Purchases of investments	(218,330)	(373,976)
Proceeds from maturities of investments	338,320	250,293
Net cash provided by (used in) investing activities	118,413	(130,225)
Financing activities
Proceeds from debt issuance, net	95,000	48,000
Proceeds from issuance of common stock, net		380,552
Debt issuance costs paid		(557)
Proceeds from issuance of common stock pursuant to equity award plans, net	14,635	17,563
Payment of public offering cost		(387)
Dividends to Noncontrolling interest (SRX Cardio)'s shareholders	(140)
Net cash provided by financing activities	109,495	445,171
Net (decrease) increase in cash, cash equivalents and restricted cash	(34,769)	155,533
Cash, cash equivalents and restricted cash at beginning of period	181,741	188,658
Cash, cash equivalents and restricted cash at end of period	$ 146,972	$ 344,191